share_log

Salarius Pharmaceuticals Q4 2023 GAAP EPS $(0.22) Beats $(1.01) Estimate

Moomoo 24/7 ·  Mar 22 16:07

Salarius Pharmaceuticals (NASDAQ:SLRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(1.01) by 78.22 percent.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment